The meeting of the German Society of Human Genetics (gfh) was held in Weimar, Germany this week and of course the attendees had the opportunity to visit the joined booth of MetaSystems and MetaSystems Probes. Main topics of the exhibition have been the latest advancements of the Neon case and imaging platform and RapidHyb, the revolutionary fast hybridization times of MetaSystems Probes' FISH probes.
XL ERBB2 (HER2/NEU) amp
- Order Number
- Package Size
- 100 µl (10 Tests)
The XL ERBB2 (HER2/NEU) amp probe detects amplifications in the long arm of chromosome 17. The orange labeled probe is designed to hybridize to the ERBB2 (HER2/NEU) locus at 17q12. A green labeled probe hybridizes to the 17cen region and functions as a control probe.
This probe is intended for methanol/acetic-acid fixed cells and tissue sections.
Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale.
Amplification or over-expression of the ERBB2 (HER2/NEU) gene occurs in approximately 15 - 30 % of breast cancers. It is strongly associated with increased disease recurrence and a poor prognosis. Over-expression is also known to occur in ovarian, stomach, and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
ERBB2 located on the long arm of human chromosome 17 (17q12), is a member of the epidermal growth factor receptor (EGFR/ErbB) family which is composed of four plasma membrane-bound receptor tyrosine kinases. Signaling through the ErbB family of receptors promotes cell proliferation and opposes apoptosis.
ERBB2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin®).
- Solid Tumors (Solid Tumors)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
Two green (2G), one orange (1O), and orange signal clusters, indicating amplification of ERBB2 (homogenous staining region = HSR).
Aberrant Cell (typical results): Two green (2G) and multiple copies of orange signals, indicating amplification of ERBB2 (double minutes = dm).
- Isola et al (1999) Clin Cancer Res 5:4140-4145
- Blancato et al (2004) Br J Cancer 90:1612-1619
- Singhi et al (2012) Mod Pathol 25:378-387